Obama cut and run. Maliki should not have been given a

New Post Public Reply Private Reply Replies (1) Message Board
Bhawks cashclan #1908
Quote:
Obama cut and run. Maliki should not have been given a choice if the US stayed..



Really? Didn't' we claim that we overthrew Saddam so that Iraqis could have a chance at democracy? So how then could we thwart the will of the Iraqi parliament, who were insisting that American forces would be subject to Iraqi laws?

Yeah, that'd work. Arrests/'hostage taking and the usual 'free range' IED casualties/deaths.

I'm always amazed at how readily conservatives want to put at risk other peoples kids, for dubious causes. Really, Iraqis were worth continued loss of American lives by 2011?

And comparisons with garrisoning the ROK are silly. That was and is a homogenous, NON-SECTARIAN society, in no way similar to post-Saddam Iraq

Quote:
Condoleezza Rice, who served as Bush’s secretary of state, wrote in her 2011 book, “No Higher Honor,” that Bush did not want to set a deadline “in order to allow conditions on the ground to dictate our decisions.” She wrote that she met with Maliki in August 2008 and secured what she thought was an agreement for a residual force of 40,000 U.S. troops. But she said Maliki soon “reneged” and insisted on “the withdrawal of all U.S. forces by the end of 2011.” She said Bush “swallowed hard” and agreed to what she called “suitable language” to do just that.


Rice, “No Higher Honor,” 2011: We’d given quite a lot of ground on issues such as a withdrawal timetable, consenting to the removal of all U.S. forces by the end of 2011, and we even conceded a limited level of Iraqi legal jurisdiction over our troops. … Ultimately, the compromises we made proved beneficial because the resulting [Status of Forces Agreement] put the end of the war in sight and left the new U.S. president a firm foundation for a successful conclusion of our presence there.

So, President Bush reluctantly agreed to a withdrawal deadline without leaving behind a residual force because of Maliki’s strong objections. Jeb Bush ignores those facts.

Leon Panetta, who was Obama’s defense secretary from July 2011 to February 2013, wrote in his 2014 book, “Worthy Fights,” that as the deadline neared “it was clear to me — and many others — that withdrawing all our forces would endanger the fragile stability” in Iraq. As a result, the Obama administration sought to keep 5,000 to 10,000 U.S. combat troops in Iraq, as Sullivan said in his statement.

But negotiations with Iraq broke down in October 2011 over the issue of whether U.S. troops would be shielded from criminal prosecution by Iraqi authorities. Panetta wrote that Maliki insisted that a new agreement providing immunity to U.S. forces “would have to be submitted to the Iraqi parliament for its approval,” which Panetta said “made reaching agreement very difficult.”
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 29

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 28

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 24

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 35

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 30

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 20

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Endava Investors: Legal Action Could Recover Your Losses

Updated Category News Views 87

Endava got tangled in a class action lawsuit over securities fraud back in 2024. Investors were already feeling the squeeze as whispers about declining demand for its services echoed through the trading floor. You know how it goes—when rumors hit, shares take a dive faster than you can blink. Class Action Reality: Who Gets to Play? The lawsuit targeted shareholders who...

Continue Reading
New Mortgage Ratings Assigned to Deephaven Trust Portfolio

Updated Category News Views 177

Introduction to Deephaven Residential Mortgage Trust 2024-1 In an important development within the non-prime mortgage market, KBRA has recently assigned preliminary ratings to eight classes of mortgage-backed notes from Deephaven Residential Mortgage Trust 2024-1 (DRMT 2024-1). This $514.6 million transaction comprises a unique pool of 1,330 residential mortgages,...

Continue Reading
Meta Platforms Declares Cash Dividend for Shareholders

Updated Category News Views 325

Quarterly Cash Dividend Announcement from Meta Platforms The board of directors of Meta Platforms, Inc. (NASDAQ: META) has recently declared a quarterly cash dividend of $0.525 per share, benefitting shareholders holding both Class A and Class B common stock. This dividend reflects the company's ongoing commitment to returning value to its shareholders. Dividend Payment...

Continue Reading
Campine Expects Strong Financial Upsurge in 2024 Performance

Updated Category News Views 125

Campine NV Forecasts Impressive Growth in 2024 Campine NV, a well-known name in the metals recycling and specialty chemicals sector, is gearing up for a promising financial year ahead. The company has recently indicated that it anticipates higher profits in 2024, thanks to favorable market conditions. Projected Revenue Growth for 2024 According to Campine's expectations,...

Continue Reading
Thumzup Media's Strategic Investment in Dogecoin Ahead of ETFs

Updated Category News Views 147

Thumzup Media's Strategic Move into Dogecoin Thumzup Media Corporation (Nasdaq: TZUP) has made headlines with its latest purchase of Dogecoin, securing around 7.5 million tokens valued at approximately $2 million. This significant acquisition marks the company's first open-market investment in Dogecoin, reflecting a strong belief in the digital currency's potential for...

Continue Reading